[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"m-health\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:m-health":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100634103","exercise-targeted-smart-lifestyle-management-100634103",false,"NCT07535333","Exercise-Targeted Smart Lifestyle Management","Study on the Improvement Effects of Intelligent Lifestyle Management, Targeting Exercise Capacity Enhancement, on Overweight\u002FObesity With Metabolic Syndrome","Inclusion Criteria:\n\n* Aged between 20 and 60 years.\n* Overweight or obese, with a Body Mass Index (BMI) ≥ 24 kg\u002Fm² and \\\u003C 40 kg\u002Fm².\n* Patients with impaired metabolic parameters regarding glucose, lipids, and blood pressure，meet at least two of the following criteria:\n\n  * Central obesity: Waist circumference ≥ 90 cm for males or ≥ 85 cm for females.\n  * Hyperglycemia: Fasting plasma glucose (FPG) ≥ 6.1 mmol\u002FL, or 2-hour plasma glucose ≥ 7.8 mmol\u002FL during an oral glucose tolerance test (OGTT), and\u002For currently receiving treatment for previously diagnosed diabetes.\n  * Hypertension: Blood pressure ≥ 130\u002F85 mmHg, and\u002For currently receiving treatment for previously diagnosed hypertension.\n  * Elevated fasting triglycerides (TG): ≥ 1.7 mmol\u002FL.\n  * Reduced fasting high-density lipoprotein cholesterol (HDL-C): \\\u003C 1.04 mmol\u002FL.\n\nExclusion Criteria:\n\n* History of cardiovascular or cerebrovascular disease, or in the acute phase, including: angina pectoris, myocardial infarction, coronary revascularization surgery, stroke (ischemic or hemorrhagic, including transient ischemic attack), symptomatic peripheral artery disease requiring surgery or diagnosed via angiographic techniques, ventricular arrhythmias, uncontrolled atrial fibrillation, congestive heart failure (New York Heart Association class III or IV), hypertrophic cardiomyopathy, history of aneurysm with diameter ≥ 5.5 cm, or history of aneurysm surgery.\n* Malignancy or history of malignancy within the past five years.\n* Religious restrictions or dysphagia preventing adherence to the recommended diet.\n* Contraindications to exercise, such as orthopedic disorders.\n* Participation in other weight-loss programs (\\> 5 kg weight loss) within the six months prior to the screening visit.\n* History of bariatric surgery or intention to undergo bariatric surgery within the next 12 months.\n* History of small or large bowel resection or inflammatory bowel disease.\n* Obesity due to endocrine disorders of unknown cause (excluding treated hypothyroidism).\n* Allergy to any food components of the Mediterranean diet.\n* Immunodeficiency or HIV positive status.\n* Cirrhosis or liver failure.\n* Severe psychiatric disorders, including schizophrenia, bipolar disorder, eating disorders, or depression requiring hospitalization in the past 6 months.\n\nSevere comorbidities with a life expectancy of less than 24 months.\n\n* Alcoholism, addiction, or drug abuse in the past six months (or daily alcohol consumption \\> 50 g).\n* History of major organ transplantation.\n* Concomitant use of immunosuppressive or cytotoxic medications.\n* Current use of systemic corticosteroids.\n* Current use of weight-loss medications.\n* Currently participating in another randomized clinical trial.\n* Patients with acute infection or inflammation (e.g., pneumonia) may -participate 3 months after resolution of the condition.\n* Pregnant or planning to become pregnant during the study period.\n* Any other condition that may interfere with protocol compliance.\n* Refusal to sign the informed consent document.","ALL","20 Years","60 Years",{"count":20,"type":21},435,"ESTIMATED","INTERVENTIONAL",[24],"NA","To investigate the effects of simple dietary management and diet combined with exercise capacity-targeted intelligent lifestyle management on improving metabolic indicators in patients with overweight\u002Fobesity and metabolic syndrome.",[27,28,29,30,31],"M-health","Metabolic Syndrome","Lifestyle Alteration","Lifestyle (Sedentary Behavior and Physical Activity)","Overweight , Obesity",[33,28,34,35,31],"mhealth","Lifestyle (sedentary behavior and physical activity)","Mediterranean Diet","NOT_YET_RECRUITING","2026-04-09",{"date":39,"type":40},"2026-04-17","ACTUAL",{"date":42,"type":21},"2026-05",{"date":44,"type":21},"2027-06",{"name":46,"class":47},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100607231","prevention-of-anxiety-and-depression-over-risk-assessment-100607231","NCT07185867","Prevention of ANxiety and Depression Over Risk Assessment","Prevention of ANxiety and Depression Over Risk Assessment: a Randomized Controlled Trial (the PANDORA-Predict-Plus-Prevent Study)","Inclusion Criteria:\n\n* Informed consent acceptance\n* Having a valid telephone number\n* Ownership of an Apple-Android-operating smartphone with an internet connection\n* 18-65 years old\n* Habitually reside (\\> 6 months\u002Fyear) in Spain or Chile\n\nExclusion Criteria:\n\n* Difficulty reading and\u002For understanding Spanish\n* Suffer from disabling neurological conditions (dementia, blindness, etc.) that makes it difficult to use smartphone, terminal illness with a life expectancy \\\u003C 12 months, a history of severe mental disorders confirmed by a healthcare professional (schizophrenia or psychosis, bipolar, anoxeria, bulimia or personality disorders), having alcohol or substance use disorder within the past year\n* Currently receiving face to face or via internet psychological treatment (currently taking antidepressants or anxiolytics is not an exclusion criterion, but their use will be taken into account throughout the follow-up)\n* Presence of clinically relevant anxiouys (GAD-7 score ≥ 10 points) or depressive symptoms (PHQ-9 score ≥ 10 points).",true,"18 Years","65 Years",{"count":59,"type":21},2595,[24],"The general goal is to design, develop and evaluate a personalized, self-guided and trans-diagnostic internet-based intervention to prevent anxiety and depression, based on predictive risk algorithms and decision support systems (DSS), in Spanish and Chilean adult population.\n\nMethods: We will conduct a three-arm parallel randomized controlled trial with one year of follow-up. A total of 2,595 depression- or\u002Fand anxiety-free participants (865 per group), aged 18-65, will be recruited and randomly assigned to one of two intervention groups or to the usual-care group (in a 1:1:1 ratio). Both interventions, Pandora-1 and Pandora-2, will be implemented via a smartphone application, the Pandora App. Pandora-1 is a self-guided and transdiagnostic intervention that includes 4 interactive intervention modules (move more, sleep better, improve relationships and emotional well-being), as well as predictive risk algorithms, decision support systems, and monitoring and feedback to implement personalized plans for the prevention of anxiety and depression. Pandora-2 is a psycho-educative intervention with predictive risk algorithms, minimally interactive and without personalization. The primary outcome is the combined rate of the onset of anxiety or depression (DSM-V diagnoses as measured by the CIDI interview) at 6 and 12 months. The secondary outcomes are the reduction of depressive (PHQ-9) and anxious (GAD-7) symptoms, risk of depression and anxiety (predictD and predictA risk algorithms), and the improvement of mental \\& physical quality of life (SF-12), as well as acceptation and satisfaction with Pandora apps (u-MARS) and adverse effects (ad hoc questionnaire), which will be assessed at 1, 6 and 12 months. As mediators will be measured social support (Duke-UNC-2 items), physical activity (BPAQ-2), sleep (AIS-5), and repetitive negative thinking (PTQ-9) evaluated at 1, 6 and 12 months. We will use ActiGraph-GT3X accelerometers to assess physical activity and sleep at 1 and 6 months, in a subsample of 404 sedentary study participants.",[63,64,65,66],"Depression","Anxiety","Prevention","m-Health",[63,64,65,68,66,69,70],"Randomized Controlled Trial","App","Predictive risk algorithms","2025-09-15",{"date":73,"type":40},"2025-09-22",{"date":75,"type":21},"2026-02-15",{"date":77,"type":21},"2028-03-07",{"name":79,"class":80},"The Mediterranean Institute for the Advance of Biotechnology and Health Research","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":81},"100492117","innovative-approaches-in-diabetes-care-100492117","NCT05687968","Innovative Approaches in Diabetes Care","Inclusion Criteria:\n\n1. 20 years old or older\n2. Pre-diabetes or diabetes\n3. Taiwan nationality or fluent in Mandarin or Taiwanese\n4. Not pregnant or breastfeeding\n5. Capable (or assisted by a caregiver) of using a smartphone to photograph and record meals\n\nExclusion Criteria:\n\n1. Eating disorders\n2. Undergoing treatment for severe illnesses that could affect normal dietary intake (e.g., cancer)\n3. Unable to use a smartphone to take photos and record food intake.",{"count":89,"type":21},39,[24],"In Taiwan, an estimated 2.3 million individuals have diabetes, with a 44% increase observed among young adults and adolescents. Poor dietary habits and sedentary lifestyles are major risk factors for type 2 diabetes. The widespread use of smartphones has facilitated the development of digital health technologies, including digital food photography and artificial intelligence (AI), which show promise for personalized nutrition care and health promotion. While such technologies have demonstrated short-term success in diabetes management, their long-term effectiveness remains uncertain.\n\nThis study aims to evaluate the effectiveness of a digital eHealth care intervention for individuals with diabetes. Participants will be recruited from the Diabetes Shared Care Network and community care centers in Taiwan and followed for 12 months. Eligible participants will be randomly assigned by computer to either a control or an eHealth care group.\n\n• eHealth Group: Receives a 10-minute digital nutrition education session using the lab-developed \"3D\u002FAR MetaFood food portion education platform\" (https:\u002F\u002Fsketchfab.com\u002Fsusanlab108\u002Fcollections) and is required to submit weekly dietary records through food images using the \"Formosa FoodAPP.\" Participants will receive immediate dietary feedback from nutritionists, followed by AI-generated personalized feedback on the glycemic index (GI) and glycemic load (GL) of their meals. They will also be provided with educational videos on healthy eating, physical activity, and selecting low-GI\u002FGL foods.\n\nAnthropometric measurements and baseline questionnaires will be collected at enrollment. Blood biochemistry, including HbA1c, will be measured at baseline, and at 3, 6, 9, and 12 months. Collected food image data will be used to train AI systems for real-time dietary feedback and to explore the relationship between nutrient intake and long-term glycemic control.",[93,94,27],"Type 2 Diabetes","AI-supported Real-time Dietary Feedback",[96,97,27],"Diabetes Mellitus","AI-supported real-time dietary feedback","RECRUITING","2025-07-24",{"date":101,"type":40},"2025-07-30",{"date":103,"type":40},"2022-10-19",{"date":105,"type":21},"2025-10-01",{"name":107,"class":80},"Taipei Medical University"]